Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 1H2027 | First half of 2027 |
| 2Q26 | Second quarter of 2026 |
| AAAAI | American Academy of Allergy, Asthma & Immunology |
| ACAAI | American College of Allergy, Asthma & Immunology |
| ACE | Angiotensin-converting enzyme |
| ADA | Antidrug antibody |
| ADN | Acide désoxyribonucléique (deoxyribonucleic acid) |
| AE | Adverse event |
| AE-BK | Bradykinin-mediated angioedema |
| AE-QoL | Angioedema Quality of Life Questionnaire |
| AECT | Angioedema Control Test |
| Ago2 | Argonaute 2 |
| AHFS | American Hospital Formulary Service |
| ALT | Alanine aminotransferase |
| AOH | Angio-œdème héréditaire (hereditary angioedema) |
| ARN | Acide ribonucléique (ribonucleic acid) |
| ASO | Antisense oligonucleotide |
| ASP | Average sales price |
| AST | Aspartate aminotransferase |
| ATE | Arterial thromboembolism |
| Big4 | Big Four (Department of Veterans Affairs, Department of Defense, Public Health Service, and Coast Guard) price |
| BK2 | Bradykinin B2 |
| BLA | Biologics license application |
| BMI | Body mass index |
| C1-INH | C1 esterase inhibitor |
| C1INH | C1 esterase inhibitor |
| C4 | Complement component 4 |
| CAP | Capsule |
| CDMO | Contract development manufacturing organization |
| CI | Confidence interval |
| CK | Creatine phosphokinase |
| CL/F | Total apparent body clearance |
| CRISPR | Clustered regularly interspaced short palindromic repeats |
| D1 | Day 1 |
| DFG | Débit de filtration glomérulaire (glomerular filtration rate) |
| DNA | Deoxyribonucleic acid |
| EAACI | European Academy of Allergy and Clinical Immunology |
| ECA | Enzyme de conversion de l'angiotensine (angiotensin-converting enzyme) |
| ECG | Electrocardiogram |
| ED | Emergency department |
| eDiary | Electronic diary |
| ELISA | Enzyme-linked immunosorbent assay |
| EoS | End of study |
| ER | Emergency room |
| EU | European Union |
| F12 | Coagulation factor XII gene |
| FDA | Food and Drug Administration |
| FFP | Fresh frozen plasma |
| FSS | Federal Supply Schedule |
| FXII | Coagulation factor XII |
| GalNAc | N-acetylgalactosamine |
| HA | Hereditary angioedema |
| HADS | Hospital Anxiety and Depression Scale |
| HAE | Hereditary angioedema |
| HAE-1 | Hereditary angioedema type 1 (C1 inhibitor deficiency) |
| HAE-2 | Hereditary angioedema type 2 (C1 inhibitor dysfunction) |
| HAE-C1-INH | Hereditary angioedema due to C1 inhibitor deficiency |
| HAE-C1INH | Hereditary angioedema due to C1 inhibitor deficiency |
| HAE-FXII | Hereditary angioedema associated with a factor XII gene variant |
| HAE-nC1-INH | Hereditary angioedema with normal C1 inhibitor |
| HAE-nC1INH | Hereditary angioedema with normal C1 inhibitor |
| HAE-nl-C1INH | Hereditary angioedema with normal C1 inhibitor |
| HAE-PLG | Hereditary angioedema associated with a plasminogen gene variant |
| HAEA | Hereditary Angioedema Association |
| HCPCS | Healthcare Common Procedure Coding System |
| HDI-SF | Hamilton Depression Inventory-Short Form |
| HRQoL | Health-related quality of life |
| HV | Healthy volunteer |
| ICER | Institute for Clinical and Economic Review |
| INH | Inhibitor |
| INJ | Injection |
| IRC | Insuffisance rénale chronique (chronic kidney disease) |
| ITT | Intent-to-treat |
| IU | International units |
| IV | Intravenous |
| KK | Kallikrein |
| KKS | Kallikrein-kinin system |
| KLKB1 | Kallikrein B1 gene |
| LE | Laryngeal edema |
| LIN | Limite inférieure de la normale (lower limit of normal) |
| LLOQ | Lower limit of quantification |
| LTP | Long-term prophylaxis |
| MCID | Minimal clinically important difference |
| mRNA | Messenger RNA |
| NDA | New drug application |
| NDC | National Drug Code |
| NHP | Nonhuman primate |
| NMA | Network meta-analysis |
| NOAEL | No-observed-adverse-effect level |
| ODT | On-demand treatment |
| OLE | Open-label extension |
| OMIM | Online Mendelian Inheritance in Man |
| OR | Odds ratio |
| ORPHA | Orphanet |
| PBO | Placebo |
| PD | Pharmacodynamics |
| pdC1-INH | Plasma-derived C1 inhibitor |
| pdC1INH | Plasma-derived C1 inhibitor |
| PDUFA | Prescription Drug User Fee Act |
| Ph1 | Phase 1 |
| PICF | Participant information and consent form |
| PK | Pharmacokinetics |
| PKK | Prekallikrein |
| PKK-KK | Prekallikrein-kallikrein |
| PLG | Plasminogen gene |
| PPPY | Per patient per year |
| PR | Electrocardiographic interval from the onset of the P wave to the onset of the QRS complex |
| Q2W | Every 2 weeks |
| Q3 | Third quarter |
| Q3M | Every 3 months |
| Q4 | Fourth quarter |
| Q4W | Every 4 weeks |
| Q6M | Every 6 months |
| Q8W | Every 8 weeks |
| Q12W | Every 12 weeks |
| Q24W | Every 24 weeks |
| QALY | Quality-adjusted life-year |
| QoL | Quality of life |
| QRS | Electrocardiographic complex of ventricular depolarization (Q, R, and S waves) |
| QT | Electrocardiographic interval from the onset of the QRS complex to the end of the T wave |
| QTcF | QT interval corrected for heart rate by the Fridericia formula |
| REC | Research ethics committee |
| RISC | RNA-induced silencing complex |
| RNA | Ribonucleic acid |
| RNase H1 | Ribonuclease H1 |
| RWE | Real-world evidence |
| SAD | Single ascending dose |
| SAE | Serious adverse event |
| SC | Subcutaneous |
| SD | Standard deviation |
| SDP | Solvent detergent plasma |
| SEC | Securities and Exchange Commission |
| SEM | Standard error of the mean |
| SERPING1 | Serpin family G member 1 gene (encodes C1 inhibitor) |
| SF-12 | 12-Item Short Form Health Survey |
| siRNA | Small interfering RNA |
| SOLN | Solution |
| SUCRA | Surface under the cumulative ranking curve |
| TEAE | Treatment-emergent adverse event |
| TSQM-II | Treatment Satisfaction Questionnaire for Medication, version II |
| UK | United Kingdom |
| ULN | Upper limit of normal |
| US | United States |
| VIL | Vial |
| VTE | Venous thromboembolism |
| W3 | Week 3 |
| W5 | Week 5 |
| W9 | Week 9 |
| W13 | Week 13 |
| W17 | Week 17 |
| W21 | Week 21 |
| W25 | Week 25 |
| WAC | Wholesale acquisition cost |
| WAO | World Allergy Organization |
| WHO | World Health Organization |
| WPAI-GH | Work Productivity and Activity Impairment-General Health questionnaire |
| XR | Extended release |
| YE2027 | Year-end 2027 |